| This week's sponsor is Premier Research. | | | Rare Cancer Drug Research: What to Know Going In
Rare cancer drug research requires oncology and rare disease expertise and careful attention to trial design and regulatory demands. Get started with our white paper. Premier Research. It's what we do. Best. |
Today's Rundown | Publisher’s Note: In preparation for the new GDPR taking effect this month, we would like to reconfirm your subscription to our newsletter(s). Please click this link to reconfirm your subscription. For more information about GDPR, please visit this page.
Editor’s Note: FierceBiotech won't be publishing on Monday for the holiday. We hope everyone has a great and safe Memorial Day weekend. | |
|
Celgene’s R&D report card ‘somewhat disappointing,' say analysts Magenta eyes $100M IPO to help ‘lead a new era in transplant medicine’ Pivotal bioVenture Partners debuts $150M China-focused biotech fund [Sponsored] Growing Requirements for Medicines for Children After AL amyloidosis flop, Prothena slashes workforce by 57% AstraZeneca's Imfinzi survival win shores up the one lung cancer advantage it has EuroBiotech Report—AstraZeneca-Amgen, Celgene-Evotec, Novo deal, T cell financing and Allergy data FiercePharmaAsia—Astellas job cuts, GSK vet’s $260M Chinese startup, Sun's Zytiga knockoff Chutes and Ladders—Lilly's oncology chief announces retirement Featured Story | | | Friday, May 25, 2018 An audit of Celgene’s R&D over the last five years has revealed that two-thirds of its programs failed—and it made no difference whether the project originated in-house or externally. |
|
|
Top Stories Friday, May 25, 2018 Coming off the back of a healthy financing round just six weeks ago, stem cell biotech Magenta Therapeutics now wants more, and it wants to go public. Friday, May 25, 2018 Pivotal bioVenture Partners has raised a $150 million venture fund to help early-stage life science companies located within China. Monday, May 21, 2018 Progress has been made in developing medicines for children with the passing of pediatric regulation, but gaps still exist. Here’s what you need to know about recent updates from an expert at Synteract. Friday, May 25, 2018 After a turbulent year, Prothena is getting ready to cut its employees by 57% in a reorganization aimed at refocusing its resources to advance what remains in its neuroscience pipeline. Friday, May 25, 2018 AstraZeneca’s immunotherapy Imfinzi already has an FDA approval for inoperable lung cancer patients who've responded to chemo and radiation—and that's something none of its rivals will be able to say for a while. Friday, it hit another key benchmark to stretch out that lead. Thursday, May 24, 2018 In this week's EuroBiotech Report, AstraZeneca dumps solid tumor drug, Celgene, Evotec ink cancer pact, Novo bags kidney drug and more. Friday, May 25, 2018 Astellas will cut 600 positions in Japan in an R&D and sales reorg; a GSK infectious disease veteran launches wins $260M to launch a China-focused biotech; Sun Pharma wins an FDA green light for its knockoff version of Johnson & Johnson's prostate cancer drug Zytiga; and more. Friday, May 25, 2018 Lilly's oncology chief announced her retirement; a GSK veteran is launching a Chinese public health startup with $260 million; and Gilead's longtime R&D chief is leaving to go back to his roots—plus more hirings, firings and retirings throughout the industry. | This week's sponsor is IQVIA. | | | |
Resources Sponsored by: Seton Hall Law 4-day interactive educational program trusted by multi-national companies as part of their compliance training for employees. Explore legal, regulatory and ethical issues faced by pharmaceutical, biotech and medical device manufacturers operating globally. Visit event homepage for session topics. Presented by: Patheon There are many parenteral dosage forms from which the pharmaceutical scientist can choose to develop their drug product. In this article, the author discusses the choices available and strategies which can be employed at the different stages of development. Sponsored by: Veeva Systems Learn how to reduce change management burden, keep systems current, and maintain compliance by applying a risk-based approach to change management of GxP systems. Sponsored by: Veeva Systems UCB took a more holistic approach to managing regulatory processes. Read how their efforts are paying off. Sponsored by: Veeva Systems Find out how to eliminate regulatory’s tracking spreadsheets for good. Sponsored by: Veeva Systems Learn how cloud-enabled solutions provide real-time insights and actionable analytics to improve clinical trial safety and performance in this short presentation. Sponsored by: Docusign Life science companies are experiencing a significant transformation in how they bring new products to market. Drug Approval, Manufacturing Quality & Regulation 2018 | Online Building your Program for Immunomodulating Therapeutics Wednesday, 6 June, 2018 | Paris, France BIO International Convention June 4-7, 2018 | Boston, MA
FierceBiotech Executive Breakfast at BIO 2018 – CAR-T 2.0: Innovation Never Stands Still June 6, 2018 | Boston, MA BioBasics: Biotech for the Non-Scientist June 13-14, 2018 | Toronto, Canada The Liquid Biopsy Summit June 20–22, 2018 | San Francisco, CA Sensors Expo & Conference Conference & Expo: June 26-28, 2018 | Pre-Conference Symposia: June 25, 2018 | San Jose, CA FierceBiotech 3rd Drug Development Forum October 1–3, 2018 | Hilton Boston Logan Airport Hotel | Boston, MA Drug Development Boot Camp® 2018 November 14-15, 2018 | Boston, MA | Register and start preparing Today! | 